Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Sales of Investments

Cash received from selling or redeeming investments.

Janux Therapeutics, Inc.NASDAQ: JANX

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments growth accelerates

Q1 FY2026 sales of investments of $121.31M rose 287.9% year over year, ahead of the +176.4% change in trailing-twelve-month sales of investments. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.

Context

  • Sales of investments amounted to 4052.8% of revenue in FY2025, up 2041.9 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +287.9% holds above the trailing-twelve-month pace of +176.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$121.31M-20.7% QoQ
Last fiscal yearDec 2025
$405.28M+90.4% YoY
LTMMar 2026
$495.32M+176.4% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+287.9%——
1 year+90.4%——
3-year CAGR+4.1%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
405.28M USD
Year-over-year change
+90.4%
4-year CAGR
+31.8%

Sales of Investments vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +176.4% is the highest of 10, against a peer median of -49.2%.
  • Sales of investments amounts to 2291.8% of revenue for JANX, versus a peer median of 318.8%.
JANX Competitors
Sales of Investments for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$1.02B USD-79.1%+105.5%75.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$502.67M USD-21.3%+28.6%448811.6%
JANXJanux Therapeutics, Inc.LTM Mar 2026$495.32M USD+176.4%+4.1%2291.8%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$306.48M USD-49.2%+5.7%—
IMTXImmatics N.V.LTM Mar 2026€282.39M EUR-50.0%+246.5%757.1%
STROSutro Biopharma, Inc.LTM Mar 2026$263.81M USD-56.8%+18.0%264.9%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$148.16M USD+10.9%+27.4%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$132.5M USD-49.2%+10.0%372.8%
MGNXMacroGenics, Inc.LTM Mar 2026$125.44M USD-4.7%-21.0%79.9%
IMNMImmunome, Inc.LTM Sep 2026$54M USD-81.1%——
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-49.2%+22.7%318.8%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Depreciation & Amortization113K841K1.96M2.06M2.03M
Deferred Income Tax00000
Stock-Based Compensation6.91M17.2M20.01M33.02M40.22M
Change in Working Capital8.84M4.28M(6.55M)685K6.71M
Accounts Receivables8M0000
Inventory831K0000
Accounts Payables2.14M(294K)277K1.58M977K
Other Working Capital(2.13M)4.57M(6.83M)(899K)5.74M
Other Non-Cash Items(169K)(2.18M)(7.69M)(10.59M)(17.57M)
Operating Cash Flow(16.98M)(42.92M)(50.58M)(43.81M)(82.24M)
Capital Expenditures(1.48M)(6.45M)(1.85M)(359K)(1.04M)
Acquisitions (Net)339.48M(64.71M)000
Purchases of Investments(473.63M)(294.39M)(317.34M)(470.58M)(705.22M)
Sales of Investments134.15M359.1M278M212.92M405.28M
Other Investing Activities(339.48M)64.71M000
Investing Cash Flow(340.96M)58.27M(41.19M)(258.02M)(300.98M)
Debt Repayment00000
Common Stock Issued204.17M500K56.53M698.27M5.29M
Common Stock Repurchased0000(347K)
Dividends Paid00000
Other Financing Activities1.81M03.02M14.97M0
Financing Cash Flow386.52M500K59.55M713.24M4.95M
Effect of Forex Changes00000
Net Change in Cash28.59M15.84M(32.22M)411.4M(378.27M)
Free Cash Flow(18.46M)(49.37M)(52.43M)(44.17M)(83.28M)

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.